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Background: The Forkhead box M1 (FOXM1), an important regulator of cell differentiation and proliferation, is
overexpressed in a number of aggressive human carcinomas. The purpose of this study was to examine the
expression levels of FOXM1 in epithelial ovarian cancer (EOC), to identify the relationship between FOXM1
expression and patient survival, and to investigate the role of FOXM1 in human ovarian cancer development.
Methods: Immunohistochemical analysis for FOXM1 was performed in a total of 158 ovarian tissue specimens, all
with linked clinical outcome data. Kaplan–Meier method and Cox proportional hazards analysis were used to relate
FOXM1 expression to clinicopathological variables and to progression-free survival (PFS) and overall survival (OS).
In vitro studies were performed to determine the function of FOXM1 in cell proliferation, migration and invasion in
EOC cells using pcDNA3.1-FOXM1 and FOXM1 shRNA.
Results: Elevated FOXM1 levels were associated with lymph node metastasis (P = 0.009), but not with age, FIGO
stage, histological grade and histological type. Patients with high expression of FOXM1 had poorer PFS (P = 0.0001)
and OS (P < 0.0001) than patients with low expression of FOXM1. Furthermore, multivariate analyses indicated that
FOXM1 positivity was an independent prognostic factor for PFS (P = 0.046) and OS (P = 0.022), respectively.
Overexpression of FOXM1 increased expression and activity of matrix metalloproteinase-2 (MMP-2), MMP-9 and
vascular endothelial growth factor-A (VEGF-A), and cancer cell proliferation, migration and invasion of HO-8910 cells,
whereas knockdown of FOXM1 reduced expression and activity of MMP-2, MMP-9 and VEGF-A, and cancer cell
proliferation, migration and invasion of HO-8910 PM cells.
Conclusions: Our results suggest that FOXM1 expression is likely to play important roles in EOC development and
progression. FOXM1 expression is a potential prognostic factor for PFS and OS, and it could be a novel treatment
target in EOC patients.
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Ovarian cancer is the leading cause of death among
gynecologic malignancy in the world, with increasing
incidence recently in China [1]. Most patients are diag-
nosed with late-stage disease due to the silent early
stage and easy metastasis [2]. Epithelial ovarian cancer
(EOC) account for nearly 70% of all ovarian malignant
diseases. Despite improvements in surgical techniques
and the advent of more targeted therapeutic agents,
therapeutic failure and disease progression are still quite
frequent [3]. Therefore, there is an urgent requirement
to identify extra prognostic indicators and to improve
on current understanding of the molecular mechanisms
underlying EOC. It would be very helpful for patients
with advanced disease.
Forkhead box protein M1 (FOXM1), also known as
HFH-11, MPP-2, WIN, and Trident, is a typical tran-
scription factor that belongs to the Forkhead Box family,
which is evolutionarily conserved and is defined by hav-
ing a common DNA-binding domain called Forkhead or
winged-helix domain [4,5]. FOXM1 is well-known for
its critical role in cell cycle progression by regulating
the transition from G1 to S phase and G2 to M phase
progression, as well as to mitosis [5,6]. Gene expression
profiling revealed that elevated expression of FOXM1
was observed in a multitude of malignancies [7]. It has
been reported that FOXM1 promotes tumor progres-
sion in malignancies [5,8-11]. Furthermore, overexpres-
sion of FOXM1 correlated with disease progression and
poor prognosis and could serve as an independent pre-
dictor of poor survival in various human malignancies
[12-16]. However, the clinical relevance of FOXM1
expression has not been investigated in patients with
EOC.
In this study, we used an immunohistochemical
method to determine the expression of FOXM1 in EOC
specimens from 158 patients. The aim of this study was
to determine the expression level of FOXM1 in EOC
and to examine its association with clinicopathologic
variables as well as to assess the utility as prognostic
indicator. We further probed the biological features
of FOXM1 by assaying cell proliferation, migration,
invasion and potential mechanism underlying this. In
this report, we showed that up-regulation of FOXM1
increased MMP-2, MMP-9 and VEGF-A expression
whereas knockdown of FOXM1 by FOXM1 shRNA
decreased MMP-2, MMP-9 and VEGF-A expression.
In addition, the results supported a mechanism for
the FOXM1-induced cell migration and invasion that
involved induction of MMP-2, MMP-9 and VEGF-A
expression. The results presented here help to evaluate
the suitability of FOXM1 as prognostic marker and
therapeutic target in EOC.Methods
Patients and tissue samples
The study has been performed with the approval of the
Fourth Military Medical University ethics committee.
Informed consent was obtained from each patient before
sample collection. For real-time PCR and western blot
analysis, we collected data on 68 patients, including
epithelial ovarian cancer (46 cases) and normal ovary
(22 cases), treated at Xijing Hospital between Novem-
ber 2009 and June 2011. For immunohistochemical
analysis, a total of 158 pathological specimens of EOC
were obtained from the pathological archives at Xijing
Hospital between May 2004 and July 2006. None of
patients had received preoperative chemotherapy. The
median age of patients at the time of surgery was
53 years (range, 26–79 years). Histological grades were
assigned according to the International Federation of
Gynecology and Obstetrics (FIGO) classification. The
follow-up interval was calculated from the date of sur-
gery to the date of death or last clinical evaluation.
Tumour progression was defined based on clinical,
radiological or histological diagnosis.
Immunohistochemistry
Immunohistochemical staining was performed using
the streptavidin-peroxidase conjugate method. Surgical
specimens were fixed in 10% formalin and embedded in
paraffin. Briefly, after 4 μm-thick sections were deparaf-
finized in dimethylbenzene and rehydrated in an alcohol
series, antigens were retrieved by boiling in a citrate
buffer (0.01 M, pH = 6.0). Endogenous peroxidase activ-
ity was blocked with 0.3% hydrogen peroxide in metha-
nol, and nonspecific immunoglobulin binding was
blocked by incubation with 10% normal goat serum for
15 min. After rinsing with PBS, the sections were incu-
bated at room temperature for 60 min with FOXM1
polyclonal rabbit-anti-human antibody (ProteinTech
Group, China) at 1:100 dilution. After a PBS rinse, slides
were then incubated for 25 min at room temperature with
biotinylated goat-anti-rabbit immunoglobulin (Zhongshan
Biotechnology, China) followed by incubation with
peroxidase-conjugated streptavidin for 20 min and with
fresh 0.05% 3, 3′-diaminobenzidine (DAB). Slides then
were counterstained with Mayer’s hematoxylin and
mounted on a crystal mount. As negative control for
the staining procedure, the primary antibody was omit-
ted. As positive controls epithelial ovarian cancer tissue
that showed positive staining in earlier staining proce-
dures was used. The percentage of cells positive for
FOXM1 expression was graded and counted as follows:
1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Two
pathologists who were blind of patients’ profiles observed
the slides. The staining intensity score was graded as
follows: 0 (no signal), 1 (weak), 2 (moderate), and 3
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ing intensity were multiplied to obtain a final score,
which determines FOXM1 expression as (- = 0; + =
1-4; ++ = 5-8; +++ = 9-12). In this study, we grouped
all of the samples into the high expression group (++
or +++) and the low expression group (- or +) accord-
ing to the protein expression.
Cell lines and cell culture
ES-2, OVCAR-3, OVCA429, OVCA420 ovarian cancer
cells were purchased from the American Type Culture
Collection. HO-8910 and HO-8910 PM (a highly meta-
static cell line derived from HO-8910) ovarian cancer cells
were purchased from the Cell Bank of Type Culture
Collection of the Chinese Academy of Sciences (Shanghai,
China) [17]. All cell lines were incubated at 37°C under
5% CO2 in either minimum essential medium or Dul-
becco’s modified Eagle medium with 10% fetal bovine
serum and 1% Penicillin-Streptomycin.
ShRNA and cDNA plasmid transfections
The coding regions of FOXM1 were inserted into
pcDNA3.1 (Clontech). HO-8910 cells transfected with
empty vectors (pcDNA3.1) were used as a control.
HO-8910 PM cells were transfected with FOXM1 shRNA.
A nonspecific control was used as non-targeting shRNAs.
Transfections were performed with Lipofectamine 2000
reagent (Invitrogen, USA) using 1–2 mg of expression
vector/ml serum-free medium as described by the manu-
facturer. The transfected cells were incubated for 24 h and
harvested for real time PCR and western blot analysis.
Gelatin zymography
MMP-2 and MMP-9 enzymatic activities in the cell cul-
ture medium were determined by SDS-PAGE gelatin
zymography. After transfection with pcDNA3.1-FOXM1
or FOXM1 shRNA for 24 h, cells were continuously
incubated in serum-free DMEM at 37°C for 24 h. The
conditioned medium was then collected and centri-
fuged to remove cells and debris, and 30 μg of total
protein was resolved in 7.5% polyacrylamide gels con-
taining 0.1% gelatin. After electrophoresis, the enzymes
were renatured by incubation with 2.5% Triton X-100
for 30 min at room temperature. The gels were then
incubated in 50 mM Tris–HCl (pH = 7.5), containing
150 mM NaCl, 0.5 mM ZnCl2 and 10 mM CaCl2, for
24 h at 37°C. Gels were stained with coomassie blue
and then destained with 10% acetic acid and 20%
methanol in water. MMP-2 and MMP-9 activities were
quantified by densitometry.
RT-PCR
Total RNA was isolated from cultured cells with Trizol
reagent (Invitrogen, USA). RT-PCR was performed usingthe Invitrogen SuperScript one-step RT-PCR kit accord-
ing to manufacture’s instruction. The PCR conditions
were as follows: 94°C for 2 min; 30 cycles of 94°C for
30 s, 56°C for 30 s, and 72°C for 60 s; and a final step of
10 min at 72°C. PCR products were analyzed using agarose
gel electrophoresis and cloned into the pMD18-T
(TaKaRa) vector for sequencing. The following primers
were used: for FOXM1, 5′-GCGACAGGTTAAGGTT
GAG-3′ (forward); 5′-AGGTTGTGGCGGATGGAGT-3′




Quantitative real-time PCR was carried out using real-
time PCR with the SYBR Green reporter. The GAPDH
was used as an internal control for each specific gene.
Three independent experiments were performed to
analyze the relative gene expression and each sample
was tested in triplicate. The primers used for PCR were
as follows: FOXM1 forward 5′-GCGACAGGTTAA
GGTTGAG-3′; reverse 5′-AGGTTGTGGCGGATG
GAGT-3′; MMP-2 forward 5′-TGATCTTGACCA
GAATACCATCGA-3′; reverse 5′-GGCTTGCGAGGG
AAGAAGTT-3′; MMP-9 forward 5′-CCTGGAGAC
CTGAGAACCAATC-3′; reverse 5′-CCACCCGAGT
GTAACCATAGC-3′; VEGF-A forward 5′-CTTGCCT
TGCTGCTCTACC-3′; reverse 5′-CACACAGGATGG
CTTGAAG-3′; GAPDH forward 5′-GCACCGTCAA
GGCTGAGAAC-3′; reverse 5′-TGGTGAAGACGCC
AGTGGA-3′. Quantification was calculated using the
comparative threshold cycle (Ct) method and efficiency
of the RT reaction (relative quantity, 2- ΔΔCt).
Western blot analysis
Cells were lysed in lysis buffer (phosphate-buffered
saline containing 1% Triton X-100, protease inhibitor
cocktail, and 1 mM phenylmethylsulfonyl fluoride) at
4°C for 30 min. Lysate protein concentration was esti-
mated using BCA protein assay kit (Pierce, USA). Equal
amounts of protein were electrophoresed under non-
reducing conditions on 10% acrylamide gels, followed
by transfer to a PVDF membrane on a semidry transfer
apparatus. After being blocked with 5% nonfat milk for
1 h at room temperature, the membrane was incubated
with antibodies against FOXM1, MMP-2, MMP-9, and
VEGF-A (ProteinTech Group, China) with proper dilu-
tions for 1 h, respectively. After washing, horseradish
peroxidase-conjugated anti-rabbit IgG (Sigma, USA)
was used as a secondary antibody and then incubated
with the membrane for 1 h at room temperature. The
immunoreactive proteins were then detected using the
ECL system. Densitometric analysis of immunoblots
was performed by using Quantity One software.
Wen et al. Journal of Translational Medicine 2014, 12:134 Page 4 of 13
http://www.translational-medicine.com/content/12/1/134Wound-healing assay
An in vitro wound-healing assay was used to assess cell
motility. Ovarian cancer cells were plated at equal dens-
ity in 24-well plates and grown to confluence. Wounds
were then generated with a sterile pipette tip, cells were
rinsed two times with PBS and fresh culture medium
was added. Photos were taken at different time points
under microscopy, and the wound healing was measured
at 0 h, 12 h, 24 h, and 36 h. The experiment was done in
triplicate.
Cell migration and invasion assays
A Transwell system that incorporated a polycarbonate
filter membrane with a pore size of 8 μm (BD Biosciences,
USA) was used to assess cell migration and invasion [18].
For cell invasion assays, after 24 h transfection, cells were
seeded on the upper chamber at a density of 3.0 × 105
cells/well in serum-free medium. Medium containing 10%
fetal bovine serum medium was applied to the lower
chamber as chemoattractant. After 48 h incubation at
37°C, non-invasive cells remaining on the upper surface
of the membrane were removed by wiping with cotton-
tipped swabs. Cells which invaded through the matrix
gel and were adherent to the lower surface of the filter
were fixed with methanol, stained with 0.5% crystal violet,
photographed, and counted. Cell migration assay was
performed according to the protocol described above,
except that the cells were added into the inserts with
24 h incubation without matrix gel pre-coated. Each test
group was assayed in triplicate.
Statistical analysis
Tests for association between immunohistochemical
expression and clinicopathologic variables were com-
puted using χ2-test or Fisher’s exact test. PFS and OS
curves were calculated with the Kaplan-Meier method
and were analyzed with the log-rank test. Univariate
analysis and multivariable models were fit using a Cox
proportional hazards regression model. The results are
presented as means ± SD. The statistical significance of
differences was determined by Student’s t-test in 2 groups
and oneway ANOVA in multiple groups. P < 0.05 was con-
sidered statistically significant. All data were analyzed with
SPSS 13.0 software.
Results
Clinical significance of FOXM1 expression in EOC
As shown in Figure 1A, FOXM1 was mainly expressed
in the cytoplasm and nucleus of EOC cells using immu-
nostaining. In the majority of cases, ovarian cancer cells
showed both a cytoplasmic and nuclear staining for
FOXM1, but staining was restricted to cytoplasm or
nuclear in a few cases. By definition, we grouped all of
the samples into the high expression group (both acytoplasmic and nuclear staining for FOXM1) and the
low expression group according to the protein expres-
sion. The correlation between FOXM1 expression and
clinicopathological parameters such as age, FIGO stage,
grade, histological type and lymph node status was
summarized in Table 1. The expression of FOXM1 in
patients with lymph node metastasis was significantly
higher than in patients without lymph node metastasis
(P = 0.009). The Kaplan-Meier survival analysis showed
that FOXM1 expression had a significant adverse effect
on survival (PFS, P = 0.0001, Figure 1B; OS, P < 0.0001,
Figure 1C). By using univariate Cox proportional ana-
lysis, FOXM1 expression was statistically correlated to
survival (PFS, P = 0.001, Table 2; OS, P = 0.001, Table 3).
Multivariate Cox analysis showed that FIGO stage,
lymph node metastasis and FOXM1 expression were
independent risk factors that influenced the prognosis
of EOC (Table 2 and 3).
Expression levels of FOXM1 in ovarian cancer cells and
ovarian tissues
To assess the FOXM1 expression levels, we compared
the levels of FOXM1 expression in normal ovarian
tissues, ovarian cancer tissues and ovarian cancer cell
lines by real-time PCR and western blot analyses.
Expression levels of FOXM1 mRNA and protein were
shown to be significantly increased in ovarian cancer tis-
sues compared with normal ovarian tissues (Figure 1D
and 1E). We further detected the expression of FOXM1 in
ovarian cancer cells. FOXM1 was detectable in all these
six cell lines, with highest expression in HO-8910 PM
cells. As shown in Figure 2A and 2C, expression of
FOXM1 protein and mRNA in HO-8910 cell line was
lower than that in its subline cell line HO-8910 PM
(a highly metastatic cell line derived from HO-8910,
P < 0.001). We then detected the expression of FOXM1
in these same cells using RT-PCR assay (Figure 2B).
MMP-2, MMP-9 and VEGF-A expression after transfection
with FOXM1
HO-8910 cells were either untransfected (Mock), or
transfected with pcDNA3.1 (control) or pcDNA3.1-
FOXM1 (FOXM1), as shown in Figure 3 and Figure 4.
After transfection of cells, real-time PCR and western
blot analyses were performed to analyze the expression
levels of FOXM1 mRNA and protein. As shown in
Figure 3A and 3B, the expression of FOXM1 mRNA
and protein was significantly increased in pcDNA3.1-
FOXM1-transfected cells compared with pcDNA3.1-
transfected cells and untransfected cells (P < 0.001,
P < 0.01, respectively). Moreover, we investigated the
protein expression and mRNA expression of MMP-2,
MMP-9 and VEGF-A by real-time PCR and western
blot analyses. As shown in Figure 3A, the expression of
Figure 1 FOXM1 expression level and its prognostic effects in epithelial ovarian cancer. A Representative immunohistochemical stainings
of FOXM1 in ovarian cancer (-, +, ++, +++). Scale bars = 0.1 mm. B Kaplan-Meier progression-free survival curves for FOXM1-negative patients with
EOC (n = 57) and FOXM1-positive patients with EOC (n = 101). C Kaplan-Meier overall survival curves for FOXM1-negative patients with EOC (n = 57)
and FOXM1-positive patients with EOC (n =101). D The FOXM1 protein expression was higher in 46 EOC tissues than in 22 normal ovarian
tissues (P = 0.0056). E The relative mRNA expression of FOXM1 was higher in 46 EOC tissues than in 22 normal ovarian tissues (P < 0.0001).
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FOXM1-transfected cells was increased compared to
those in pcDNA3.1-transfected cells and untransfected
cells (P < 0.001, P < 0.01, P < 0.05, respectively). Similar
results were observed by real-time quantitative PCR ana-
lysis as well, as shown in Figure 3C, 3D and 3E (P < 0.001).
To investigate the effects of FOXM1 transfection on
MMP-2 and MMP-9 enzyme activities, gelatin zymogra-
phy were performed to examine the activities of MMP-2
and MMP-9 using conditioned medium, which was
collected and measured after 24 h transfection. The results
showed that MMP-2 and MMP-9 enzymatic activities
were significantly increased in pcDNA3.1-FOXM1-trans-
fected cells, compared to those in pcDNA3.1-transfected
cells and untransfected cells (Figure 4B, P < 0.01).
Effects of FOXM1 overexpression on cell proliferation,
migration and invasion
To confirm the effects of FOXM1 overexpression on cell
proliferation, FOXM1 was overexpressed in HO-8910cells after transfection with pcDNA3.1-FOXM1. The
cells were assessed for cell proliferation by MTT assay.
Our results revealed that pcDNA3.1-FOXM1-trans-
fected cells showed a significantly higher proliferation
rate than pcDNA3.1-transfected cells and untransfected
cells (Figure 4A).
Next, we determined the effects of FOXM1 overex-
pression on tumor cell metastasis. Cellular migration
was analysed by wound-healing assay while invasi-
veness was analysed with transwell experiments. The
results of wound-healing assay and transwell migration
assay demonstrated that HO-8910 cells that were
transfected with the pcDNA3.1- FOXM1 plasmid
exhibited a significant increase in cellular migration
as compared with control cells (Figure 4C and 4D,
P < 0.01). In the in vitro invasion assays, the number
of cells invaded through the transwell membrane in
pcDNA3.1-FOXM1-transfected group was significantly
higher than those in the control group (Figure 4E,
P < 0.05).
Table 1 Relationship between FOXM1 protein expression
with clinicopathological features of patients
Characteristic No. FOXM1 protein expression P
Negative Positive
Age 0.922
<60 99 36 63
≥60 59 21 38
FIGO stage 0.127
I + II 44 20 24
III + IV 114 37 77
Grade 0.298
G1 24 12 12
G2 46 16 30
G3 88 29 59
Histological type 0.481
Serous 69 27 42
Nonserous 89 30 59
Lymph node metastasis 0.009*
Negative 120 50 70
Positive 38 7 31
*P < 0.05.
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with FOXM1 shRNA
HO-8910 PM cells were either untransfected (Mock), or
transfected with nonspecific shRNA (control) or FOXM1
shRNA (shRNA), as shown in Figure 5 and Figure 6.
After transfection for 24 h, real-time PCR and western
blot analyses were performed to analyze the expression
levels of FOXM1 mRNA and protein. As shown in
Figure 5A and 5B, the expression of FOXM1 mRNATable 2 Univariate and multivariate analyses of PFS in patien




FIGO stage I + II










PFS progression-free survival, aHR = hazard ratio, bCI = confidence interval, *P < 0.05.and protein was significantly decreased in FOXM1 shRNA-
transfected cells compared with control shRNA-transfected
cells and untransfected cells (P < 0.01). Moreover, we
investigated the protein expression and mRNA expres-
sion of MMP-2, MMP-9 and VEGF-A by real-time PCR
and western blot analyses. As shown in Figure 5A, the
expression of MMP-2, MMP-9 and VEGF-A protein in
FOXM1 shRNA-transfected cells was decreased com-
pared to those in control shRNA-transfected cells and
untransfected cells (P < 0.01, P < 0.05, P < 0.01, respect-
ively). Similar results were observed by real-time quan-
titative PCR analysis as well, as shown in Figure 5C, 5D
and 5E (P < 0.01, P < 0.001, P < 0.01, respectively). To
investigate the effects of FOXM1 shRNA transfection on
MMP-2 and MMP-9 enzyme activities, gelatin zymogra-
phy were performed to examine the activities of MMP-2
and MMP-9 using conditioned medium, which was col-
lected and measured 24 h after transfection. The results
showed that MMP-2 and MMP-9 enzymatic activities
were significantly reduced in FOXM1 shRNA-transfected
cells, compared to those in control shRNA-transfected
cells and untransfected cells (Figure 6B, P < 0.01).
Effects of FOXM1 silencing on cell proliferation, migration
and invasion
To confirm the effects of FOXM1 silencing on cell pro-
liferation, FOXM1 was down-regulated in HO-8910 PM
cells using shRNA against FOXM1 transcripts. The cells
were assessed for cell proliferation by MTT assay. Our re-
sults revealed that FOXM1 shRNA-transfected cells showed
a significantly lower proliferation rate than control shRNA-
transfected cells and untransfected cells (Figure 6A).
Next, we determined the effects of FOXM1 silencing
on tumor cell metastasis. Cellular invasiveness andts with epithelial ovarian cancer
P Multivariate analysis P
b HRa 95% CIb
12 0.744 — — —
59 0.001* 1.789 1.170-2.733 0.007*
81 0.735 — — —
13 0.309 — — —
96 0.744 — — —
03 <0.001* 2.308 1.531-3.480 <0.001*
29 0.001* 1.494 1.007-2.215 0.046*
Table 3 Univariate and multivariate analyses of OS in patients with epithelial ovarian cancer
Variables Categories Univariate analysis P Multivariate analysis P
HRa 95% CIb HRa 95% CIb
Age <60
≥60 1.236 0.868-1.761 0.239 — — —
FIGO stage I + II
III + IV 2.263 1.467-3.490 <0.001* 1.996 1.285-3.099 0.002*
Grade G1
G2 1.056 0.608-1.833 0.847 — — —
G3 1.234 0.744-2.049 0.416 — — —
Histological type Serous
Nonserous 1.108 0.780-1.573 0.568 — — —
Lymph node metastasis Negative
Positive 2.856 1.922-4.243 <0.001* 2.142 1.411-3.251 <0.001*
FOXM1 Negative
Positive 1.960 1.338-2.871 0.001* 1.599 1.069-2.391 0.022*
OS overall survival, aHR = hazard ratio, bCI = confidence interval, *P < 0.05.
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transwell assays, respectively. The results of wound-
healing assay and transwell migration assay demon-
strated a significant reduction in motility of FOXM1
shRNA-transfected cells compared with the controlFigure 2 Expression levels of FOXM1 in ovarian cancer cells. A Express
western blot. Levels of tubulin were evaluated as an internal control for loa
cancer cells. Β-actin was amplified as a control. C Expression levels of FOXM
expression levels were normalized against GAPDH. Columns mean derived fro
was done using Student’s t tests. ***P < 0.001, significant.groups (Figure 6C and 6D, P < 0.01). In the in vitro
invasion assays, the number of cells invaded through
the transwell membrane in FOXM1 shRNA-transfected
group was significantly lower than those in the control
group (Figure 6E, P < 0.01).ion levels of FOXM1 proteins in ovarian cancer cells detected by
ding. B RT-PCR analysis of FOXM1 mRNA expression levels in ovarian
1 mRNA in ovarian cancer cells detected by real-time PCR. The mRNA
m at least three independent experiments, bars, SD. Statistical analysis
Figure 3 Effects on MMP-2, MMP-9 and VEGF-A expressions of HO-8910 cells after transfection with FOXM1. HO-8910 cells were either
untransfected (Mock), or transfected with pcDNA3.1 (control) or pcDNA3.1-FOXM1 (FOXM1). A Western blot demonstrated FOXM1, MMP-2, MMP-9 and
VEGF-A protein levels were significantly increased after transfection with FOXM1. The tubulin was analyzed as a control. B-E FOXM1, MMP-2, MMP-9
and VEGF-A mRNA expression levels of HO-8910 cells after transfection with FOXM1 were quantified by real-time PCR using GAPDH as a reference.
Statistical significance was assessed using one-way ANOVA. Data are presented as mean ± SD for three independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001, statistically significant difference.
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Previous studies have shown that the expression of
FOXM1 was increased in different types of cancer.
Importantly, some studies also have evaluated the prog-
nostic significance of FOXM1 in several types of cancer
[12-16]. However, the clinical significance of FOXM1
expression in EOC had not been determined prior to
this study. This is the first study determining the influ-
ence of FOXM1 expression on the prognosis of EOC. In
this study of 158 patients with EOC with long-term
follow-up available, we analyzed the prognostic signi-
ficance of FOXM1 expression in terms of survival and
its association with clinicopathologic variables. FOXM1
protein expression was examined immunohistochemically
in EOC, and FOXM1 was mainly located in the nucleus
and cytoplasm. A statistically significant relationship wasfound for FOXM1 expression with lymph node metastasis
and FOXM1 expression was significantly associated
with patients’ survival (PFS, P = 0.0001, Figure 1B; OS,
P < 0.0001, Figure 1C). Several studies have now been
published that FOXM1 expression correlates with tumor
stage, grade and may have prognostic utility [19-23].
Correlations between FOXM1 and clinicopathologic
parameters have been reported in ovarian cancer, but
the results were inconsistent [20]. Our results indicated
FOXM1 expression to be significantly associated with
lymph node metastasis (P = 0.009), but not with FIGO
stage (P = 0.127) and grade (P = 0.298). The discrepancy of
immunohistochemical results may be explained partly
by the different antibody used, because they used mono-
clonal antibody. Another limitation of our study was the
relatively small population of patients that we evaluated.
Figure 4 Effects on cell proliferation, migration, invasion and MMP-9/MMP-2 activities of HO-8910 cells after transfection with FOXM1.
HO-8910 cells were either untransfected (Mock), or transfected with pcDNA3.1 (control) or pcDNA3.1-FOXM1 (FOXM1). A Cell proliferation rates
were determined by MTT assay. B HO-8910 cells were incubated with serum-free media for 24 h and conditioned media were collected and
subjected to gelatin zymography. Zymographic analysis showed increased MMP-2 and MMP-9 activity in FOXM1-transfected HO-8910 cells. C
Wound healing assays were done to determine the effects on cell migration of HO-8910 cells after transfection with FOXM1. The wound gaps
were measured at six reference points along the wound, and the results were expressed as the average wound gap. Scale bars = 0.5 mm. D-E
HO-8910 cells were transfected with mock, control or FOXM1 and then subject to transwell migration/invasion assays, as described in Methods.
After 24/48 h, migratory/invasive cells were counted after staining with crystal violet. Scale bars = 0.1 mm. Statistical significance was assessed using
one-way ANOVA. Data are presented as mean ± SD for three independent experiments. *P < 0.05, **P < 0.01, statistically significant difference.
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http://www.translational-medicine.com/content/12/1/134In multivariate analysis, FOXM1 expression was identi-
fied as an independent prognostic factor for both PFS
and OS (Table 2 and 3). We also found that FOXM1 was
highly expressed in most primary EOC tissues but lowly
expressed in normal ovarian tissues at both the protein
(P = 0.0056, Figure 1D) and the mRNA level (P < 0.0001,
Figure 1E). These data suggests that FOXM1 may not
only be involved in the progression of EOC, but also in
the metastasis, and therefore might be a reasonable
target for directed therapeutics.
We validated the correlation between FOXM1 expres-
sion and tumor progression and metastasis by in vitro
functional studies. The following study began with the
use of real-time PCR and western blot to identify genesdifferentially expressed in two clonally related human
EOC cell lines differing in metastatic activity, and this
revealed a significant difference in FOXM1 expression.
The results showed that FOXM1 protein and mRNA were
lowly expressed in HO-8910 but were highly expressed in
its more metastatic derivative, HO-8910 PM (Figure 2A
and 2C) [17]. Diagnosis of epithelial ovarian cancer usually
occurs when the cancer has already progressed to the
advanced stages [2]. Metastasis remains the major prob-
lem in managing EOC, and invasion is the first step of
metastasis. Thus, blocking the invasion and metastasis
of cancer cells is of great significance in EOC treatment.
To test the significance of FOXM1 interference in EOC
cells, we transfected pcDNA3.1-FOXM1 plasmid and
Figure 5 Effects on MMP-2, MMP-9 and VEGF-A expressions of HO-8910 PM cells after transfection with FOXM1 shRNA. HO-8910 PM
cells were either untransfected (Mock), or transfected with nonspecific shRNA (control) or FOXM1 shRNA (shRNA). A Western blot demonstrated
FOXM1, MMP-2, MMP-9 and VEGF-A protein levels were significantly reduced after transfection with FOXM1 shRNA. The tubulin was analyzed as a
control. B-E FOXM1, MMP-2, MMP-9 and VEGF-A mRNA expression levels of HO-8910 PM cells after transfection with FOXM1 shRNA were quantified by
real-time PCR using GAPDH as a reference. Statistical significance was assessed using one-way ANOVA. Data are presented as mean ± SD for
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, statistically significant difference.
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http://www.translational-medicine.com/content/12/1/134FOXM1 shRNA into HO-8910 cells and HO-8910 PM
cells, respectively. Cell growth, migration and invasion are
important processes involved in tumor progression. In our
study, we explored whether FOXM1 contributed to cell
growth, migration and invasion of EOC cells in vitro. The
results showed that overexpression of FOXM1 by transfec-
tion with pcDNA3.1-FOXM1 could promote cell growth,
invasion and metastasis. Similarly, we found that depletion
of FOXM1 by transfection with FOXM1 shRNA could sup-
press cell growth, invasion and metastasis. Several studies
have shown that FOXM1 could promote cell growth, inva-
sion and metastasis in various cell types [4,5,24,25]. Here,
we reached the same conclusion in EOC. To our know-
ledge, this study is novel in investigating the role and mech-
anisms of FOXM1 in invasion and metastasis of EOC cells.The present study suggested that FOXM1 expression
was closely associated with increased tumor invasion,
migration and metastasis. It has been reported that a
number of FOXM1 downstream target molecules are
involved in regulating tumor progression and invasive
behaviors. In all these processes, MMP-2, MMP-9 and
VEGF-A are thought to play a critical role in EOC cells.
Among matrix metalloproteases (MMPs), a family of
zinc dependent endopeptidases, MMP-2 and MMP-9
have been considered to be critical for tumor growth,
invasion and metastasis [26,27]. It is also known that
VEGF-A is another important molecule that is involved in
tumor growth, invasion and metastasis [28,29]. More-
over, some studies have documented that overexpres-
sion of MMP-2, MMP-9 and VEGF-A was associated
Figure 6 Effects on cell proliferation, migration, invasion and MMP-9/MMP-2 activities of HO-8910 PM cells after transfection with
FOXM1 shRNA. HO-8910 PM cells were either untransfected (Mock), or transfected with nonspecific shRNA (control) or FOXM1 shRNA (shRNA).
A Cell proliferation rates were determined by MTT assay. B HO-8910 PM cells were incubated with serum-free media for 24 h and conditioned
media were collected and subjected to gelatin zymography. Zymographic analysis showed decreased MMP-2 and MMP-9 activity in HO-8910 PM
cells transfected with FOXM1 shRNA. C Wound healing assays were done to determine the effects on cell migration of HO-8910 PM cells after
transfection with FOXM1 shRNA. The wound gaps were measured at six reference points along the wound, and the results were expressed as the
average wound gap. Scale bars = 0.5 mm. D-E HO-8910 PM cells were transfected with mock, control or FOXM1 shRNA and then subject to transwell
migration/invasion assays, as described in Methods. After 24/48 h, migratory/invasive cells were counted after staining with crystal violet. Scale
bars = 0.1 mm. Statistical significance was assessed using one-way ANOVA. Data are presented as mean ± SD for three independent experiments.
*P < 0.05, **P < 0.01, statistically significant difference.
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http://www.translational-medicine.com/content/12/1/134with cancer progression and metastasis in ovarian can-
cer [30-32]. Our in vitro data indicated that the
expressions of MMP-2, MMP-9 and VEGF-A were ob-
viously increased in pcDNA3.1-FOXM1-transfected
HO-8910 cells, however they were obviously decreased in
FOXM1 shRNA-transfected HO-8910 PM cells. Previous
research has demonstrated that up-regulation of FOXM1
increased the expression of MMP-2, MMP-9 and VEGF-A,
resulting in the promotion of proliferation, migration
and invasion of cancer cells [9,15,33]. Our results
emphasize the conclusion that FOXM1 regulates the
expression of MMP-2, MMP-9 and VEGF-A in EOC cells.
These results suggest that downregulation of FOXM1could potentiate antimetastatic activity partly through
down-regulating expressions of MMP-2, MMP-9 and
VEGF-A in EOC. However, it is not clearly understood
how FOXM1 regulates the expression of MMP-2,
MMP-9 and VEGF-A in EOC cells. Further studies are
required to distinguish the possible interaction between
FOXM1 and the above proteins.
Conclusions
In summary, the present study showed that FOXM1
overexpression was associated with lymph node status and
poor patient survival in EOC. Our study demonstrated
that FOXM1 played an important role in proliferation,
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http://www.translational-medicine.com/content/12/1/134migration and invasion of EOC. Moreover, we demon-
strated that FOXM1 regulated the expression of MMP-2,
MMP-9 and VEGF-A in EOC cells. Taken together, our
results suggest that elevated FOXM1 may be a prognostic
marker of EOC and that FOXM1 may serve as a prom-
ising therapeutic target for inhibition of ovarian cancer
progression.
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